SAN FRANCISCO– surgical.ai, a permanent capital vehicle focused on surgical automation, robotics and software, today announced its meaningful participation in a $180 million Series C round for Caresyntax. Caresyntax is a leader in the fast growing data-assisted surgery category. The investment will accelerate the adoption and development of Caresyntax’s AI-enabled surgical software and fund strategic M&A activity.
Caresyntax’s data-assisted surgery platform addresses critical data shortfalls and fragmentation challenges that have hindered the progress of precision surgery across the $3 trillion global surgical market. By collecting, integrating, and analyzing comprehensive data with AI, Caresyntax provides real-time and long-term clinical decision support to improve patient journeys, increase hospital operational efficiency, and achieve better outcomes.
Caresyntax’s platform acts as a copilot for surgeons by collecting, integrating, and analyzing data before, during, and after surgical operations. By linking data from disparate sources on a unified vendor-neutral platform, Caresyntax supports surgeons in optimal preparation, helps patients understand and prepare for their procedures, and assists surgical teams in managing their workflows to minimize risk from procedural variance. The platform’s comprehensive data collection and analysis capabilities also enables post-surgical risk assessment and tailored patient care, leading to faster recovery times, reduced costs, and improved overall healthcare delivery.
Currently, Caresyntax’s software is used by over 30,000 surgical professionals across more than 3,500 operating rooms worldwide, making more than 3 million surgical procedures safer and smarter annually. The new funding will allow Caresyntax to accelerate commercial scaling and adoption of its precision surgery platform, enhance its AI and edge-to-cloud applications, and support strategic acquisitions that will expand its reach and technological offerings in the surgical automation space.
surgical.ai participated in the funding round with a combined eight figure investment alongside several leading strategic and financial investors including Symbiotic Capital, MTIP AG, Pictet Alternative Advisors, Aescuvest, PFM Health Sciences, BlackRock, Optum Ventures, Relyens, and others. (IANS)
